Patient listening on social media for patient-focused drug development: a synthesis of considerations from patients, industry and regulators
Authors:
Open Access
- 6 March 2024
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 11, 1274688
Abstract
Patients, life science industry and regulatory authorities are united in their goal to reduce the disease burden of patients by closing remaining unmet needs. Patients have, however, not always been systematically and consistently involved in the drug development process. Recognizing this gap, regulatory bodies worldwide have initiated patient-focused drug development (PFDD) initiatives to foster a more systematic involvement of patients in the drug development process and to ensure that outcomes measured in clinical trials are truly relevant to patients and represent significant improvements to their quality of life. As a source of real-world evidence (RWE), social media has been consistently shown to capture the first-hand, spontaneous and unfiltered disease and treatment experience of patients and is acknowledged as a valid method for generating patient experience data by the Food and Drug Administration (FDA). While social media listening (SML) methods are increasingly applied to many diseases and use cases, a significant piece of uncertainty remains on how evidence derived from social media can be used in the drug development process and how it can impact regulatory decision making, including legal and ethical aspects. In this policy paper, we review the perspectives of three key stakeholder groups on the role of SML in drug development, namely patients, life science companies and regulators. We also carry out a systematic review of current practices and use cases for SML and, in particular, highlight benefits and drawbacks for the use of SML as a way to identify unmet needs of patients. While we find that the stakeholders are strongly aligned regarding the potential of social media for PFDD, we identify key areas in which regulatory guidance is needed to reduce uncertainty regarding the impact of SML as a source of patient experience data that has impact on regulatory decision making.Keywords
This publication has 95 references indexed in Scilit:
- Trends in Fentanyl Content on Reddit Substance Use Forums, 2013–2021Journal of General Internal Medicine, 2023
- Analysis2019
- Gathering Structured Patient Insight to Drive the PRO Strategy in COPD: Patient-Centric Drug Development from Theory to PracticeAdvances in Therapy, 2019
- Unmet needs in the international neuroendocrine tumor (NET) community: Assessment of major gaps from the perspective of patients, patient advocates and NET health care professionalsInternational Journal of Cancer, 2019
- Recommendations for the Use of Social Media in Pharmacovigilance: Lessons from IMI WEB-RADRDrug Safety, 2019
- Evaluating Patient Experiences in Dry Eye Disease Through Social Media Listening ResearchOphthalmology and Therapy, 2019
- Incorporating Social Media into your Support Tool Box: Points to Consider from Genetics‐Based CommunitiesJournal of Genetic Counseling, 2017
- Incorporating patient preferences into drug development and regulatory decision making: Results from a quantitative pilot study with cancer patients, carers, and regulatorsClinical Pharmacology & Therapeutics, 2015
- Determinants of New Product Launch Success in the Pharmaceutical IndustryJournal of Pharmaceutical Innovation, 2015
- Using patient-reported outcomes in clinical practice: challenges and opportunitiesQuality of Life Research, 2008